GlassScriptPhysician profile
Dhaval Shah
NPI 1063743722
$10,160.80
in general payments reported to CMS, 2019-2025
30 companies · $8,906 in 2025
The $8,906 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $288 · 2021: $163 · 2022: $301 · 2023: $97.90 · 2024: $196 · 2025: $8,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Consulting Fee: $2,200 · Travel and Lodging: $1,895 · Food and Beverage: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Consulting Fee | $2,200.00 |
| Travel and Lodging | $1,894.80 |
| Food and Beverage | $605.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avyxa Pharma, LLC | $6,582.91 | 2025 | |
| Novartis Pharmaceuticals Corporation | $2,325.22 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.15 | 2020-2022 | |
| Abbvie INC. | $164.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $145.18 | 2020-2022 | |
| Incyte Corporation | $84.47 | 2020-2024 | Jakafi, Pemazyre, Monjuvi |
| Pfizer INC. | $63.09 | 2019-2024 | |
| Gilead Sciences, INC. | $57.62 | 2021-2025 | Trodelvy |
| Genzyme Corporation | $54.49 | 2020-2024 | |
| Amgen INC. | $46.02 | 2020 | |
| Genentech USA, INC. | $45.58 | 2022-2024 | Alecensa, Tecentriq |
| Merck Sharp & Dohme LLC | $42.50 | 2022 | |
| Puma Biotechnology, INC. | $41.67 | 2020 | |
| Beigene USA, INC. | $38.73 | 2020 | |
| Glaxosmithkline, LLC. | $37.16 | 2022-2023 | Ojjaara |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $28.57 | 2025 | Reblozyl |
| Syndax Pharmaceuticals, INC. | $22.75 | 2025 | Revuforj |
| Pharmacosmos Therapeutics INC. | $18.55 | 2024 | Monoferric |
| Eisai INC. | $18.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.00 | 2025 | |
| Acrotech Biopharma INC. | $16.58 | 2024 | Ryzneuta |
| Janssen Biotech, INC. | $16.58 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $15.56 | 2020 | |
| Seagen INC. | $15.45 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.97 | 2020 | |
| Sobi, INC | $13.75 | 2022 | |
| Dova Pharmaceuticals | $13.33 | 2020 | |
| Astellas Pharma US INC | $12.85 | 2019 | |
| Epizyme, INC. | $12.67 | 2020 | |
| Secura Bio, INC. | $10.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhaval Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.